Comparing Postoperative Pain Following COX-2 and Prostanoids Expression (COX2RCT)
A Prospective Randomized Clinical Trial for Comparing Postoperative Pain Following COX-2 and Prostanoids Expression in Women Who Underwent Laparoscopic Surgery for Female Genital Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hee Seung Kim, PhD
- Phone Number: 82-2-2072-4863
- Email: bboddi0311@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Hospital
-
Contact:
- Hee Seung Kim, PhD
- Phone Number: 82-2-2072-4863
- Email: bboddi0311@gmail.com
-
Contact:
- Eunji Lee, MD
- Phone Number: 82-2-2072-2643
- Email: bliss8880103@gmail.com
-
Principal Investigator:
- Hee Seung Kim, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female, Age ≥ 20 years
- Patients with benign female genital disease who need laparoscopic surgery
- Patients with benign disease who can be treated by single port laparoscopy
- Patients who signed an approved informed consent
Exclusion Criteria:
- Female, Age < 20 years
- Pregnancy
- Previous cancer history
- Patients who refuse to sign an informed consent
- Patients with benign female genital disease combined clinical peritonitis (ex. tubo-ovarian abscess, tubo-ovaritis, ruptured endometriosis)
- Patients with malignant female genital disease
- Patients who got surgery with multi-port laparoscopy
- Patients who are contraindicated with COX-2 inhibitors (liver disease, renal disease, active peptic ulcer, active gastrointestinal tract bleeding, ischemic heart disease, hyperkalemia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: COX-2 inhibitor (Celecoxib)
Celebrex; COX-2 inhibitor
|
Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
Single-port laparoscopic surgery with CO2 gas
Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
|
|
Placebo Comparator: Placebo drug (Ramnos)
Ramnos; Lactobacillus casei variety rhamnosus
|
Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
Single-port laparoscopic surgery with CO2 gas
Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of biomarkers expression according to exposure to CO2 gas
Time Frame: Peritoneal biopsy will be done twice (intraoperative, at right after trocar insertion and right before trocar removal, an average of 2-3hours)
|
Peritoneal biopsy and real-time polymerase chain reaction(RT-PCR), Immunohistochemistry of Biomarkers (COX-2, PGE2, PGF2, PGI2, TXA2)
|
Peritoneal biopsy will be done twice (intraoperative, at right after trocar insertion and right before trocar removal, an average of 2-3hours)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analogue scale(VAS) score
Time Frame: every six hours for 48 hours
|
Degree of postoperative pain (No pain : 0 / Moderate pain : 5 / Unbearable pain : 10)
|
every six hours for 48 hours
|
|
Numbers of rescue analgesia
Time Frame: From postoperation state to discharge (up to 2 days)
|
Frequency of additional pain killer (Tramadol 50mg, Ketorolac 2mg/kg)
|
From postoperation state to discharge (up to 2 days)
|
|
Postoperative complication
Time Frame: From postoperation state to discharge (up to 2 days)
|
nausea, vomiting, etc.
|
From postoperation state to discharge (up to 2 days)
|
|
Duration of hospitalization
Time Frame: From postoperation state to discharge (up to 2 days)
|
duration of hospitalization
|
From postoperation state to discharge (up to 2 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hee Seung Kim, PhD, Seoul National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- 2017-1477
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.